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The aim of the present work was to develop a programmed drug delivery system which would be able 
to release the drug after 6 h of lag time by use of hydrophilic polymers. The capsule body was made 
impermeable by use of formaldehyde vapor treatment, while the cap was untreated. The capsule was 
filled with two layered tablets (tablet-in-capsule), followed by a sodium bicarbonate:citric acid mixture 
(SBCM) and lactose as bulking agent. Sodium alginate, chitosan, HPMC K15 and chitosan:sodium 
alginate complex (CSAC) were used as the rate modulating layer. Through combined use of HPMC 
K15 and adjusting the ratio of CSAC, the desired lag time of 6 h was obtained. The effect of the bulking 
agents on the lag time were also studied and it was found that the lag time was decreased with higher 
amounts of lactose, and delayed dissolution and decreased lag time was observed at higher amount of 
effervescent mixture.
Uniterms: Circadian rhythm. Chitosan/sodium alginate complex. HPMC K15. Lactose. Effervescent 
mixture.
O objetivo do presente trabalho foi desenvolver sistema de liberação programada de cloridrato de 
verapamil capaz de liberação imediata do fármaco após 6 h de intervalo de tempo usando polímeros 
hidrofílicos. O corpo da cápsula foi impermeabilizado por tratamento de vapor de formaldeído, enquanto 
a tampa não foi submetida ao tratamento. Dois comprimidos foram inseridos na cápsula (comprimidos 
em cápsula) seguido de mistura de bicarbonato de sódio: ácido cítrico e lactose, utilizados como 
excipientes. O alginato de sódio, a quitosana, o HPMC K15 e o complexo quitosana:alginato de sódio 
foram utilizados para modular a razão de liberação do fármaco. A combinação entre o HPMC K15 e 
o ajuste da proporção do complexo quitosana:alginato de sódio permitiu a liberação do fármaco após 
6 h. O efeito dos excipientes na liberação do fármaco foi também avaliado. Verificou-se que o tempo de 
latência foi reduzido na presença de maior quantidade de lactose, enquanto o menor tempo foi observado 
empregando maior concentração da mistura efervescente.
Unitermos: Ritmo circadiano. Quitosana/complexo de alginato de sódio. HPMC-K15. Lactose. Mistura 
efervescente.
INTRODUCTION
The delivery of the desired dose of a drug at a prede-
termined time has always been the prime objective of drug 
delivery systems. Novel drug delivery systems have the 
potential to provide antihypertensive medication at the time 
when the need is greatest (Elliott, Prisant, 1997; Prisant et 
al., 1992). The disease symptoms, such as hypertension, 
ischemic heart disease, asthma and rheumatoid arthritis, 
exhibit circadian rhythms (Lemmer, 1991; Traynor et al., 
1992; Vyas et al., 1997). Cardiovascular diseases, which 
account for the greatest morbidity and mortality, are greatly 
affected by body rhythms (Muller, 1999). Moreover, treat-
ment outcomes may be affected by body rhythms. Failure 
to recognize these points may account for chronopatho-
logical events, including anterior ischemic optic neuropathy 
(Hayreh, 1999) and cerebrovascular accidents among per-
sons with hypertension whose blood pressure falls markedly 
during the night (“extreme dippers”) (Kario et al., 1996). It 
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is recognized that myocardial infarctions, sudden cardiac 
death, transient ischemic attacks and cerebrovascular ac-
cidents occur at a higher frequency in the early hours of 
the morning. Most cardiovascular medicines are designed 
to achieve a constant, or near-constant, effect throughout 
the 24-hour dosing interval. In many cases, however, the 
requirement for medication is not the same at nighttime 
as it is during the day (Anwar, White, 1998). Many drugs 
have been studied with respect to their pharmacokinetics 
and chronopharmacology, including analgesics, anticancer 
drugs, antibiotics, psychoactive drugs, local anesthetics, 
antiasthmatics, anticonvulsants and beta-blockers (Ritschel, 
Forsuz, 1994).
In general, the release rate of a drug is controlled by 
using a polymer with opposite solubility to the drug, or by 
combining polymers of different solubilities, as the drug 
will diffuse out easily from the dosage form if the fabricated 
by polymer, or polymers, have the same solubility as the 
drug. This concept was used to deliver verapamil (Verelan 
PM) by using water soluble and insoluble polymers. The 
chronotherapeutic oral drug absorption system (CODAS) 
verapamil PM, (Verelan PM, Schwarz Pharma, Inc., Me-
quon, WI) was designed to provide a drug-release profile 
that complements the circadian pattern of blood pressure 
(Prisant, 2001). This technology incorporated an initial 
4-5 h delay, followed by the extended release of verapamil.
One should not assume that a drug dosed in the 
morning will have the same antihypertensive effect as a 
drug dosed in the evening (Lemmer, 1996). Oral pulsed or 
delayed delivery systems are designed to elicit program-
mable lag phases preceding a prompt and quantitative, and 
either repeated or prolonged release of the drug (Maroni, 
2010). Therefore, the present study was aimed to develop 
a drug delivery system, using hydrophilic polymers only, 
which would be able to release the drug immediately af-
ter the desired lag time of 6 h. Verapamil was chosen as 
a representative drug, which is a potent calcium channel 
blocker and has been used for the treatment of essential 
hypertension and time related occurrence of disease symp-
toms (Lemmer, 1991).
MATERIAL AND METHODS
Material
Verapamil hydrochloride and HPMC K-15 were 
received as gift samples from Alembic Ltd. Vadodra, 
Gujarat, India. Empty capsule shells were received as 
gift samples from Erawat Pharma, Pithampur, Madhya 
Pradesh, India. Chitosan with 85% deacetylation was 
purchased from Marine chemicals, Kochi India. Sodium 
alginate was purchased from Loba chemie, Pvt. Ltd, Mum-
bai, India. All other reagents were of analytical grade and 
used as purchased.
Preparation of impermeable capsules body
For controlling the release of the drug from a novel 
tablet in capsule device, the body of the capsule was 
made impermeable, while the cap of the capsule remained 
soluble, so that dissolution fluid may enter from the soluble 
part of capsule. The body and the cap of the gelatin capsule 
(size 0) were separated. The body of the capsule was ex-
posed to formaldehyde vapor for 6 h at room temperature 
and dried at 50 °C for 48 h in a hot air oven (Sropathy et 
al., 1999). The treated capsule body and the untreated 
soluble cap were stored in desiccators until used. Prior to 
use, the treated capsule body was studied for disintegration 
test and the treated capsule body did not show any signs of 
disintegration and was therefore used for the further study.
Preparation of two layered tablets
An accurately weighed amount of the powders, con-
taining the immediate release layer and the rate modulating 
layers, were sifted through 80 mesh size, and then tablets 
were compressed in a 7 mm single punch machine by 
hand filling. The immediate release layer was composed 
of verapamil: lactose: cross povidone: magnesium stearate 
(20:65:10:5), while the rate modulating membrane was 
composed of polymers only.
Studies of the rate modulating layer
To select the material for the modulating layer, 
HPMC K15, chitosan and sodium alginate were chosen 
as candidates for the study, which are commonly used for 
controlled or sustained release (n = 6).
Studies of weight of rate modulating layer on the 
release of drug
HPMC K15, chitosan and sodium alginate alone, 
and chitosan and sodium alginate in different proportions 
at different weights (100, 150, 200 mg) were compressed. 
To obtain mechanically stable tablets, the rigidities of 
the tablets were kept in the range of 8 - 10 kg/mm2, as no 
significant effect of hardness was observed on the release 
of drug by Bin Li and co workers (Li et al., 2008). HPMC 
K15 has been studied for lag time by Mukesh C. Gohel 
(Gohel, Manhapra, 2002), which was further studied at 
the same weights to obtain the desired lag time (n = 6). 
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Studies of the amount of bulking agent on the 
release of drug
To study the amount of bulking agent on the release 
of drug, lactose and sodium bicarbonate:citric acid (1:1) 
were used as bulking agents. 150, 175 and 200 mg of 
lactose and 20, 30 and 40 mg of the effervescent mixtures 
were selected to study the effect of the amount of bulking 
agent on the release of drug (n = 6). 
Fabrication of the capsule device for two pulse 
drug release
Two layered tablets containing the immediate re-
lease and the rate modulating layer, followed by the effer-
vescent layer and lactose as filler were snuggly fitted in the 
impermeable capsule body (Fig. 1), and then the soluble 
cap was placed on the body. The first two layered tablet 
(A) was placed in the capsule body in such a way that the 
immediate release layer was facing the outer side, while 
the rate modulating layer faced inside. The layers (rate 
modulating and immediate release layer) of the second 
two layered tablet (B) were position facing the opposite 
way to first two layered tablet.
 
In vitro drug release studies of the capsules
A total of 900 mL of the dissolution medium (pH 1.2) 
was used to fill the USPXXIII dissolution apparatus. The 
capsule (n = 6) was placed in a basket and the speed was 
adjusted to 100 rpm. The temperature of the dissolution 
medium was maintained at 37 ± 0.5 °C. After 2 h stirring 
was stopped, the basket was washed with distilled water 
and the dissolution medium was replaced by phosphate 
buffer (pH 6.8), which had previously been maintained 
at simulated body temperature. Aliquots (10 mL) were 
withdrawn at 15 min time intervals and the same volume 
replaced by fresh dissolution medium.
RESULTS AND DISCUSSION
The aim of the study was to develop a pH indepen-
dent dosage form with a lag time of 6 h and fast release 
thereafter. The total weight of the layered tablet was kept 
at 200 mg for the study.
Effect of individual polymer on lag time
Results in Figure 2 show that only HPMC K15 was 
able to provide a lag time of 6 h. Only 7.5% of the drug 
was released after 6 h, which satisfies the lag time criteria, 
but slow release was obtained thereafter, with only 20% 
of the drug being released after 8 h, and complete release 
being seen after 10 h. Lactose was added to the HPMC to 
reduce the swelling of HPMC gel at 10%, 20%, 30%, 40% 
and 50% w/w, but lag time was not controlled.
From Figure 2, it was also seen that chitosan and 
sodium alginate were not able to produce the desired lag 
time at maximum weight, and that lag time was dependent 
on the pH of the medium. Sodium alginate rapidly forms a 
viscous gel on contact with aqueous media. Because of its 
high dissolution characteristics, the drug rapidly diffuses 
through the gel and released all of its active ingredient in 
3 h, at the highest weight of polymer. Chitosan dissolves 
to some extent in inorganic mineral acids, hence providing 
the higher lag time of 4 h and the drug was released by 
initial low dissolution and then erosion of chitosan.
Effect of CSAS
A combination of chitosan with sodium alginate for 
sustaining the release of theophylline has also been stud-
ied, and release was found to be independent of the pH of 
the dissolution medium (Yamota et al.,1994). From the re-
sults, shown below (Figure 3), it was found that a lag time 
FIGURE 1 - Schematic presentation of the bi-layered tablets in 
the impermeable capsule body.
FIGURE 2 - Lag time of sodium alginate, chitosan and HPMC 
K15 at 200 mg weight.
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of 3 h was obtained from CSAS at a 50:50 ratio at 200 mg 
weight. When the ratio of chitosan was increased then lag 
time was also increased, but significant increase (p < 0.05) 
was not observed. The complex produced by combining 
the chitosan and sodium alginate had no significant effect 
over chitosan and sodium alginate alone. Similar results 
were also obtained by Jittima and co-workers (Chatcha-
walsaisin et al., 2004).
Effect of HPMC K 15 and CSAS
HPMC K-15 and CSAS, when used alternately as 
the rate modulating layer, gave the desired lag time of 6 h, 
with only 8% of the drug being released from the formu-
lation, which satisfies the lag time criteria. Lag time was 
found to be independent of pH and the drug was released 
mainly by diffusion, although through a dissolution/ero-
sion mechanism.
Effect of the SBCM on lag time/dissolution
SBCM was added to hasten the release of drug 
after the desired lag time. No effect was observed at low 
amounts of SBCM (Figure 4), but at higher amounts the 
lag time was found to be reduced due to the pressure gen-
erated in the system by CO2 after dissolution of SBCM 
causing pressure on the gel matrix. Verapamil is a basic 
drug which is why the dissolution of the drug was also 
reduced as SBCM was increased.
Effect of lactose on lag time
Lactose was added as a bulking agent separately 
to ensure the proper position of the tablet in the capsule 
device, but a significant effect on the lag time of drug due 
to the amount of lactose was observed (Figure 5). The 
increasing hydrodynamic pressure in the system, due to 
dissolution of lactose, shortened the lag time.
Investigation of two pulse release
From the above results, two pulse release was 
successfully achieved (Figure 6) by using a bi-layered 
tablet containing 100 mg of immediate release layer and 
100 mg of HPMC K 15 as a rate modulating layer, fol-
lowed by 100 mg of CSAC (50:50) as a rate modulating 
layer, 100 mg of immediate release layer, and 20 mg 
SBCM and 175 mg of lactose. After 6 h of lag time, 85% 
release of drug was obtained within 15 min. Complete 
release was obtained within 30 min and the release was 
reproducible.
FIGURE 3 - Lag time of chitosan:sodium alginate polymer 
complex, in different ratio, at 200 mg weight.
FIGURE 4 - Effect of the amount of effervescent mixture on the 
lag time of the rate modulating layer containing HPMC K15 and 
CSAC (50:50) at different weights.
FIGURE 5 - Effect of the amount of lactose on the lag time of 
the rate modulating layer containing HPMC K15 and CSAC 
(50:50) at different weights.
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CONCLUSIONS
Pulsed release of a drug with variable lag time has 
been studied by various scientists. Lag time can control 
by using a polymer of opposite solubility to the drug, or 
by combining hydrophilic and hydrophobic polymers. A 
higher lag time for a water soluble drug using a hydrophilic 
polymer is always difficult, as diffusion of the drug from 
the polymer is not controlled easily. The present system is 
capable of delivering the drug after 6 h of desired lag time. 
It is known that in most people with high blood pressure, 
there is a definite rise in blood pressure upon awakening 
(also termed the “A.M.” surge), and that blood pressure 
then goes down starting in mid-afternoon, hence the pro-
posed system could be used successfully, as a once daily 
does taken at night time, i.e. 10 p.m., which would enable 
delivery of the drug in the early morning i.e. 4 a.m.
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